声明人史庆兰作为江苏华阳智能装备股份有限公司第 3 届董事会独立董事候选人，已充分了解并同意由提名人江 苏华阳智能装备股份有限公司董事会提名为江苏华阳智能装备股份有限公司（以下简称该公司）第 3 届董事会独立董 事候选人。现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下 事项： 一、本人已经通过江苏华阳智能装备股份有限公司第 3 届董事会提名委员会或者独立董事专门会议资格审查，提名人 与本人不存在利害关系或者其他可能影响独立履职情形的密切关系。 √是 □否 证券代码: 301502 证券简称: 华阳智能 江苏华阳智能装备股份有限公司 独立董事候选人声明与承诺 √是 □否 七、本人担任独立董事不会违反中共中央纪委《关于规范中管干部辞去公职或者退（离）休后担任上市公司、基金管 理公司独立董事、独立监事的通知》的相关规定。 √是 □否 八、本人担任独立董事不会违反中共中央组织部《关于进一步规范党政领导干部在企业兼职（任职） 问题的意见》的 相关规定。 √是 □否 √是 ...

证券代码: 301502 证券简称: 华阳智能 江苏华阳智能装备股份有限公司 独立董事提名人声明与承诺 提名人江苏华阳智能装备股份有限公司董事会现就提名周旭东为江苏华阳智能装备股份有限公司第 3 届董事会 独立董事候选人发表公开声明。被提名人已书面同意作为江苏华阳智能装备股份有限公司第 3 届董事会独立董事候选 人（参见该独立董事候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性文件 和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过江苏华阳智能装备股份有限公司第 3 届董事会提名委员会或者独立董事专门会议资格审查，提 名人与被提名人不存在利害关系或者其他可能影响独立履职情形的密切关系。 √是 □否 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任公司董事的情形。 √是 □否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所业务规则规定的独立董事任职资格和 条件。 √是 □ ...

证券代码: 301502 证券简称: 华阳智能 江苏华阳智能装备股份有限公司 独立董事候选人声明与承诺 声明人干为民作为江苏华阳智能装备股份有限公司第 3 届董事会独立董事候选人，已充分了解并同意由提名人江 苏华阳智能装备股份有限公司董事会提名为江苏华阳智能装备股份有限公司（以下简称该公司）第 3 届董事会独立董 事候选人。现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下 事项： 一、本人已经通过江苏华阳智能装备股份有限公司第 3 届董事会提名委员会或者独立董事专门会议资格审查，提名人 与本人不存在利害关系或者其他可能影响独立履职情形的密切关系。 √是 □否 √是 □否 五、本人已经参加培训并取得证券交易所认可的相关培训证明材料（如有）。 √是 □否 六、本人担任独立董事不会违反《中华人民共和国公务员法》的相关规定。 √是 □否 七、本人担任独立董事不会违反中共中央纪委《关于规范中管干部辞去公职或者退（离）休后担任上市公司、基金管 理公司独立董事、独立监事的通知》 ...

根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董事管理办 法》（以下简称"《管理办法》"）《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》（以下简称"《规范运作》"）等有关法律法规、规范性文件以及《江 苏华阳智能装备股份有限公司章程》（以下简称"《公司章程》"）的规定，我们作为公司第 二届董事会提名委员会的委员，对《关于公司董事会换届选举暨提名独立董事候选人的 议案》进行了认真的审阅，对独立董事候选人的任职条件和任职资格等相关材料进行了 审核，发表审查意见如下： 江苏华阳智能装备股份有限公司 第二届董事会提名委员会关于独立董事候选人 任职资格的审查意见 1、公司独立董事候选人干为民先生、史庆兰女士、周旭东先生具备《管理办法》《创 业板上市公司规范运作》规定的担任上市公司董事、独立董事的任职条件、任职资格，符 合相关法律法规规定的独立性等条件要求。 2、公司独立董事候选人干为民先生、史庆兰女士、周旭东先生的任职资格、教育背 景、工作经历、业务能力符合公司独立董事任职要求，不存在《公司法》《管理办法》《创 业板上市公司规范运作》等法律法规和《公司章程》中规定的不 ...

江苏华阳智能装备股份有限公司 第二届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 江苏华阳智能装备股份有限公司（以下简称"公司"）第二届董事会第十四 次会议于 2024 年 12 月 9 日以电子邮件和电话方式发出会议通知，会议于 2024 年 12 月 13 日下午 14：30 以现场结合通讯的会议方式在公司会议室召开。会议 应出席董事 9 人，实际出席董事 9 人，公司监事、高级管理人员列席了会议。本 次会议由董事长许云初先生主持。会议的召集和召开符合《中华人民共和国公司 法》等法律法规和《公司章程》的有关规定。 二、董事会会议审议情况 证券代码：301502 证券简称：华阳智能 公告编号：2024-033 与会董事对本次会议需审议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于公司董事会换届选举暨提名非独立董事候选人的议案》 鉴于公司第二届董事会任期即将届满，根据《公司法》等有关法律法规及《公 司章程》的有关规定，经公司董事会提名委员会进行资格审核，董事会同意提名 许云初先生、许鸣飞先生、於 ...

第二届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 江苏华阳智能装备股份有限公司（以下简称"公司"）第二届监事会第十次 会议于 2024 年 12 月 9 日以电子邮件和电话方式发出会议通知，会议于 2024 年 12 月 13 日下午 15：00 以现场表决的会议方式在公司会议室召开。会议应出席 监事 3 人，实际出席监事 3 人。本次会议由监事会主席陈洪先生主持。会议的召 集和召开符合《中华人民共和国公司法》等法律法规和《公司章程》的有关规定。 二、监事会会议审议情况 证券代码：301502 证券简称：华阳智能 公告编号：2024-035 江苏华阳智能装备股份有限公司 1、审议通过了《关于公司监事会换届选举暨提名非职工代表监事候选人的 议案》 鉴于公司第二届监事会任期即将届满，根据《公司法》等有关法律法规及《公 司章程》的有关规定，监事会拟提名王伟先生、顾文伟先生为公司第三届监事会 非职工代表监事候选人。公司第三届监事会成员任期自公司股东大会审议通过之 日起三年。 为确保监事会正常运行，在新一届监事就任前，原监 ...

Group 1: Company Overview - Jiangsu Huayang Intelligent Equipment Co., Ltd. focuses on micro-special motors, primarily applied in refrigeration, with plans to expand into medical and other fields [2]. - The company established a wholly-owned subsidiary, Jiangsu Delphi Medical Devices Co., Ltd., to develop precision drug delivery devices like electronic injection pens [2]. Group 2: Market Insights - The domestic injection pen market is expected to grow due to increasing awareness of safe medication and the steady expansion of the downstream pharmaceutical market [3]. - The company has been in the injection pen industry for nearly 15 years, with a strong brand presence and extensive customer service experience [3]. Group 3: Product Differentiation - The electronic injection pen offers advantages such as precise dosage, adjustable speed, and the ability to record medication usage, distinguishing it from mechanical injection pens [3]. - Compared to foreign competitors, the company has lower development costs and faster customization capabilities, despite similar product functionality [3]. Group 4: Financial Performance - The decline in gross margin for injection pens this year is attributed to increased production of mechanical injection pens and slight price reductions [3]. - The company is actively tracking the demand for injection pens from large domestic and international pharmaceutical enterprises, aiming to expand into mature application markets [3].

Financial Performance - The company's revenue for Q3 2024 was ¥94,090,039, a decrease of 4.93% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥4,759,282.24, down 66.14% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥2,972,313.27, a decline of 78.40% compared to the previous year[2]. - Total revenue for the third quarter reached ¥372,153,825.62, a slight increase of 0.22% compared to ¥366,364,251.19 in the same period last year[19]. - The net profit for Q3 2024 was CNY 25,203,970.09, a decrease of 47.5% compared to CNY 48,065,309.41 in Q3 2023[20]. - The total profit for Q3 2024 was CNY 27,005,614.91, down 50.1% from CNY 53,958,963.43 in the same period last year[20]. - Operating income for Q3 2024 was CNY 27,383,760.12, a decline of 48.9% compared to CNY 53,694,902.18 in Q3 2023[20]. - The company reported a decrease in sales revenue from CNY 198,108,258.08 in Q3 2023 to CNY 192,175,279.19 in Q3 2024, a decline of 3.9%[22]. Assets and Liabilities - Total assets at the end of Q3 2024 reached ¥1,041,317,068.82, an increase of 52.24% from the end of the previous year[2]. - The company's total liabilities increased to ¥223,800,292.27, up 7.88% from ¥208,029,322.11[17]. - Non-current assets totaled ¥346,563,281.94, up 20.14% from ¥288,467,454.72[17]. - Accounts receivable increased to ¥209,273,668.63, up 33.33% from ¥156,854,886.66 at the beginning of the period[16]. - Inventory levels rose to ¥111,204,277.91, an increase of 7.80% from ¥103,292,965.61[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,887[11]. - Jiangsu Huayang Investment Co., Ltd. holds 36.76% of shares, totaling 20,982,090 shares[11]. - Shanghai Fosun Chuangfu Investment Management Co., Ltd. holds 14.25% of shares, totaling 8,134,375 shares[11]. - Xu Yunchu, a natural person, holds 9.58% of shares, totaling 5,467,164 shares[11]. - Xu Mingfei, a natural person, holds 5.18% of shares, totaling 2,955,224 shares[11]. - The total number of restricted shares at the beginning of the period is 42,812,500, with 738,898 shares released during the period[14]. - The total number of unrestricted shares held by the top 10 shareholders is 42,812,500[14]. - The company has a significant shareholder relationship among the top shareholders, including family ties[12]. - The company has no changes in the number of restricted shares for major shareholders during the reporting period[14]. - The company plans to release restricted shares on specific future dates, with the earliest being February 2, 2025[14]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥23,509,602.30, a decrease of 50.66% compared to the same period last year[2]. - The company's cash and cash equivalents rose significantly to ¥95,831,025.93 from ¥21,204,331.68, marking an increase of 352.06%[16]. - Cash flow from operating activities for Q3 2024 was CNY 23,509,602.30, down 50.7% from CNY 47,647,966.02 in Q3 2023[22]. - Cash flow from investing activities showed a net outflow of CNY 270,889,979.29 in Q3 2024, compared to a net outflow of CNY 45,319,539.77 in Q3 2023[22]. - Cash flow from financing activities generated a net inflow of CNY 320,103,081.95 in Q3 2024, significantly higher than CNY 1,200,548.12 in Q3 2023[23]. - The company received CNY 373,106,983.87 in cash from financing activities in Q3 2024, compared to CNY 5,880,000.00 in Q3 2023[23]. Expenses - The company experienced a 50.40% increase in sales expenses, totaling ¥5,461,298.44, primarily due to higher advertising and travel costs[7]. - Total operating costs increased to ¥347,193,732.00, up 9.69% from ¥316,515,486.26 year-over-year[19]. - Research and development expenses were reported at ¥14,984,359.11, slightly down from ¥15,114,109.85 year-over-year[19]. Investment Income - Investment income surged by 586.72% to ¥346,116.35 due to increased financial investments[9].

证券代码：301502 证券简称：华阳智能 江苏华阳智能装备股份有限公司 投资者关系活动记录表 编号：2024-007 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a 15% increase compared to the same period in 2023[7]. - The company has set a revenue target of RMB 1.2 billion for the full year 2024, which reflects a 10% growth from the previous year[7]. - The company's operating revenue for the reporting period was ¥278,063,786.62, representing a 3.99% increase compared to ¥267,399,733.40 in the same period last year[13]. - Net profit attributable to shareholders decreased by 39.94% to ¥20,436,142.62 from ¥34,026,036.01 year-on-year[13]. - The cash flow from operating activities dropped by 49.97% to ¥19,049,438.55 compared to ¥38,076,931.60 in the previous year[13]. - The gross profit margin for the first half of 2024 was reported at 35%, a slight decrease from 37% in the same period last year[7]. - The net profit attributable to shareholders for the first half of 2024 was ¥22,650,807.01, up from ¥18,364,492.84 in the first half of 2023, reflecting a growth of 23.5%[123]. - The total profit for the first half of 2024 was ¥23,789,525.57, compared to ¥20,461,837.50 in the same period of 2023, indicating an increase of 11.3%[122]. Market Expansion and Strategy - User data indicates a growth in active users by 20%, reaching 1.2 million users by the end of June 2024[7]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2025[7]. - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance the company's production capacity by 30%[7]. - The company is actively expanding its international market presence and has made breakthroughs in new sales channel construction[18]. - The company is expanding its micro-special motor and components business into new areas such as kitchen appliances and security monitoring, but has only achieved limited sales so far[55]. Research and Development - The company is investing RMB 50 million in research and development for new technologies in the next fiscal year[7]. - The company has developed a new gearbox component that enhances motor drive effectiveness and improves the smoothness of operations[18]. - The company is collaborating with multiple GLP-1 drug development firms to advance syringe projects, indicating a strong pipeline for future revenue[19]. - The company is diversifying its R&D efforts across various sectors, including home appliances and medical devices, to enhance growth potential and market adaptability[33]. - The company will continue to invest in research and development to enhance product competitiveness and develop proprietary technologies[76]. Financial Position and Assets - Total assets increased by 51.26% to ¥1,034,586,206.48 from ¥683,982,603.44 at the end of the previous year[13]. - Net assets attributable to shareholders rose by 70.69% to ¥812,131,964.60 from ¥475,802,407.26 year-on-year[13]. - The total liabilities at the end of the reporting period were 62,000,000.00 CNY, indicating a manageable debt level[135]. - The total equity at the end of the reporting period was 422,741,498.25 CNY, showing an increase from the previous year's total equity of 408,742,888.06 CNY[132]. Cash Flow and Financing - The company reported a significant increase in cash flow from financing activities, up 15,601.57% to 318,902.27 million yuan, attributed to IPO fundraising[37]. - The company raised ¥373,106,983.87 from financing activities in the first half of 2024, significantly higher than the ¥5,880,000.00 raised in the same period of 2023[125]. - Cash inflow from financing activities reached CNY 403,106,983.87, a substantial rise from CNY 5,880,000.00 in the same period last year[126]. Risk Management - The management highlighted potential risks including supply chain disruptions and regulatory changes, which could impact future performance[1]. - The company is addressing raw material price fluctuation risks by optimizing supply chain management and improving inventory turnover rates[55]. - The company plans to enhance its market research and responsiveness to industry policy changes to mitigate risks associated with policy impacts on sales[56]. Shareholder and Dividend Policy - The company will not distribute cash dividends for the fiscal year 2024, focusing instead on reinvestment for growth[1]. - The company plans to distribute cash dividends of no less than 10% of the distributable profits for the year, barring special circumstances[78]. - The company’s profit distribution policy is not to be changed arbitrarily and must comply with regulations from the China Securities Regulatory Commission[79]. Corporate Governance and Compliance - The company has established a multi-tier governance structure, including a shareholders' meeting, board of directors, and supervisory board[139]. - The company has committed to timely informing about business opportunities within its main business scope[83]. - The company has not reported any environmental penalties during the reporting period[63]. - The company emphasizes its core business philosophy of "Quality Achieves Development, Innovation Creates the Future" and actively fulfills social responsibilities[64]. Share Structure and IPO - The company completed its initial public offering (IPO) of 14,271,000 shares, increasing total shares from 42,812,500 to 57,083,500[100]. - The basic earnings per share (EPS) for 2023 is reported at 1.5265 CNY, which will be diluted to 1.0358 CNY post-share increase[100]. - The largest shareholder, Huayang Investment Co., Ltd., holds 36.76% of the shares, totaling 20,982,090 shares[105]. Product Development and Innovation - New product development includes the launch of a smart automation system, expected to contribute an additional RMB 100 million in revenue by Q4 2024[7]. - The precision drug delivery device segment is expected to accelerate its growth, with applications in various medications such as insulin and growth hormones, and ongoing collaborations with pharmaceutical companies for new product development[25][26]. - The company’s commitment to quality and innovation has led to a comprehensive product line in the precision drug delivery device sector, positioning it as a leader in the domestic market[26].